Investigating the Complexity of Naloxone Distribution

Which Policies Matter for Pharmacies and Potential Recipients

Rosanna Smart, David Powell, Rosalie Liccardo Pacula, Evan D. Peet, Rahi Abouk, Corey S. Davis

ResearchPosted on rand.org Jul 25, 2024Published in: Journal of Health Economics, Volume 97, 102917 (September 2024). DOI: 10.1016/j.jhealeco.2024.102917

Despite efforts to expand naloxone access, opioid-related overdoses remain a significant contributor to mortality. We study state efforts to expand naloxone distribution through pharmacies by reducing the non-monetary costs to prescribers, dispensers, and/or potential recipients of naloxone. We find that laws that only address liability costs have small and insignificant effects on the volume of naloxone dispensed through pharmacies. In contrast, we estimate large effects of laws removing the need for patients to obtain prescriptions from traditional prescribers (e.g., primary care physicians): laws authorizing non-patient-specific prescription distribution and laws granting pharmacists prescriptive authority. We test whether areas designated as primary care shortage areas—where it would be costlier to obtain a prescription—were disproportionately impacted. Shortage areas experienced sharper growth in pharmacy naloxone dispensing in states adopting prescriptive authority policies. These gains were primarily due to those facing low out-of-pocket costs, suggesting that price barriers also must be addressed to increase naloxone purchases.

Document Details

  • Publisher: Elsevier B.V
  • Availability: Non-RAND
  • Year: 2024
  • Pages: 19
  • Document Number: EP-70557

Research conducted by

This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.